Multiple Sclerosis Queensland

European drugs watchdog finds benefits of Tysabri continue to outweigh risks

The European Medicines Agency (EMA) has finalised a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus.

Chronic cerebrospinal venous insufficiency or CCSVI is a condition identified by Dr Zamboni in 2009 that may be causing MS inflammation in some patients.

As an update on CCSVI research, Australian researchers have begun clinical testing procedures and MS Research Australia (MSRA) has been actively involved in the international review of the initial clinical findings (from Dr Zamboni) involving venous obstruction and MS.

The Australian trials, initiated in December, are Perth-based and have tested an initial cohort of 20 patients for venous obstruction. We are following these tests keenly and will report on results when available. These trials are continuing and the researchers involved may seek further funding to verify initial findings.